Variables | Univariate model | Multivariate model | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P-value | HR | 95% CI | P-value | |
Age, per 1 year increasea | 1.02 | 0.99–1.06 | 0.2330 | 1.02 | 0.97–1.06 | 0.4675 |
Sex, male (vs. female) | 0.66 | 0.36–1.22 | 0.1845 | 0.41 | 0.16–1.05 | 0.0622 |
Smoking, ever (vs. never)a | 0.63 | 0.34–1.20 | 0.1539 | |||
Baseline %FVC, per 1% increaseb | 0.97 | 0.95–0.99 | 0.0202 | 0.97 | 0.95–0.99 | 0.0168 |
Baseline %DLCO, per 1% increaseb, c | 0.99 | 0.97–1.01 | 0.3608 | |||
P/F at AE, per 10 Torr increasea | 0.96 | 0.92–0.99 | 0.0407 | 0.94 | 0.88–0.99 | 0.0240 |
C-reactive protein, per 1 mg/dLa | 1.03 | 0.99–1.06 | 0.0912 | |||
Rheumatoid factor, per 10 U/mL increasea | 1.00 | 0.99–1.01 | 0.6296 | |||
ACPA, positive (vs. negative)b, d | 1.11 | 0.40–4.65 | 0.8572 | |||
KL-6, per 100 U/mL increasea | 0.97 | 0.93–1.002 | 0.0720 | |||
UIP pattern on HRCT (vs. other patterns)b | 1.45 | 0.79–2.76 | 0.2309 | |||
Infection-triggered AEe | 1.98 | 0.58–5.14 | 0.2453 | |||
Treatment for RA before AE, yes (vs. no) | ||||||
Prednisolone ≤ 7.5 mg/day | 3.33 | 0.75–14.8 | 0.1086 | |||
Methotrexate | 0.73 | 0.37–1.37 | 0.3366 | |||
Tacrolimus | 1.24 | 0.47–2.75 | 0.6340 | |||
Bucillamine | 2.08 | 0.84–4.45 | 0.1078 | |||
Salazosulfapyridine | 1.32 | 0.63–2.55 | 0.4416 | |||
Treatment for AE (vs. CS monotherapy) | ||||||
CS + IS | 1.05 | 0.57–1.92 | 0.8826 | |||
CS + IVCY | 1.36 | 0.68–2.70 | 0.3758 | |||
CS + CNI | 0.62 | 0.26–1.35 | 0.2349 |